0002109643-26-000002.txt : 20260209 0002109643-26-000002.hdr.sgml : 20260209 20260206185920 ACCESSION NUMBER: 0002109643-26-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260209 DATE AS OF CHANGE: 20260206 EFFECTIVENESS DATE: 20260209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Embold Therapeutics, Inc. CENTRAL INDEX KEY: 0002109643 ORGANIZATION NAME: EIN: 922492735 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-572899 FILM NUMBER: 26609221 BUSINESS ADDRESS: STREET 1: 2682 EATON AVE CITY: REDWOOD CITY STATE: CA ZIP: 94062 BUSINESS PHONE: (650) 200-7297 MAIL ADDRESS: STREET 1: 2682 EATON AVENUE CITY: REDWOOD CITY STATE: CA ZIP: 94062 D 1 primary_doc.xml X0708 D LIVE 0002109643 Embold Therapeutics, Inc. 2682 EATON AVE REDWOOD CITY CA CALIFORNIA 94062 (650) 200-7297 DELAWARE None None Corporation true 2023 Gjalt W. Huisman 2682 Eaton Avenue Redwood City CA CALIFORNIA 94062 Executive Officer Director Biotechnology Decline to Disclose 06b false 2026-01-21 false true true false 0 3000000 130000 2870000 false 2 0 0 0 The gross proceeds of the offering will be used for operating expenses, working capital and other general corporate purposes. false Embold Therapeutics, Inc. Gjalt W. Huisman Gjalt W. Huisman Chief Executive Officer 2026-02-06